PRESS RELEASE 1 8 October 202 1 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has completed the submission of all information previously requested by the U.S. Food and Drug Administration (FDA) regarding  its c hemistry,

PRESS RELEASE 6 October 202 1 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming virtual investor conferences this fall. Details are as follows: Aktiespararna’s Aktiedagen Stockholm 2021 Date/Time: 11

PRESS RELEASE 1 6 September 202 1 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders’ meeting held on September 16, 2021 .

PRESS RELEASE September 16 , 2021 Today, on September 16 , 2021, the extraordinary shareholders’ meeting was held in Saniona AB . In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the extraordinary shareholders’ meeting was held only by advance voting

PRESS RELEASE 15 September 202 1 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of Wendy Dwyer as Chief Business Officer. Dwyer has more than 20 years of experience in business development , licensing, and mergers and

PRESS RELEASE August 26 , 202 1 Three Months Ended June 30, 2021 (2020) Revenue was SEK 1.9 M (2.0 M) Operating loss was SEK -103.6 M (-26.0 M) Net profit/loss was SEK -103.9 M (-23.9 M) Basic loss per share was SEK -1.67 (-0.81) Diluted loss per share was SEK -1.67 (-0.81) Six Months Ended June

PRESS RELEASE August 20 , 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the extraordinary

PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S.

PRESS RELEASE July 14 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ( $10 million ) with Formue Nord Fokus A/S.

PRESS RELEASE June 30 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a P hase 1 clinical trial of SAN711, a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine.